FDA Denies Pediatric EUA To Ocugen For Bharat Biotech's COVID-19 Vaccine Covaxin

by Vandana Singh, Benzinga Editor

March 4, 2022 9:12 AM | 1 min read |

The FDA has declined to issue an Emergency Use Authorization (EUA) for Covaxin for active immunization to prevent COVID-19 in individuals 2 to 18 years of age.
Ocugen Inc OCGN is working with the vaccine's developer, Bharat Biotech of India, to bring Covaxin to the U.S.
Related: FDA Lifts Clinical Hold On Ocugen's COVID-19 Vaccine Study In US.
Specific details to refuse the EUA were not disclosed.
Ocugen intends to continue working with FDA to evaluate the regulatory pathway for the pediatric use of Covaxin.
Price Action: OCGN shares are down 23.10% at $2.53 during the premarket session on the last check Friday.

Posted In: Biotech News Penny Stocks Health Care Small Cap FDA Movers Trading Ideas General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.